Related Experiment Video
Updated: Nov 19, 2025

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics
Mohammad Mahmoudian1, Hadi Valizadeh2, Raimar Löbenberg3
1Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Aim:
Nano drug delivery systems can provide the opportunity to reduce side effects and improve the therapeutic aspect of a variety of drugs. Bortezomib (BTZ) is a proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma. Severe side effects of BTZ are the major dose-limiting factor. Particulate drug delivery systems for BTZ are polymeric and lipidic drug delivery systems. This review focussed on lipidic-nano drug delivery systems (LNDDSs) for the delivery of BTZ.
Results:
LNDDSs including liposomes, solid lipid nanoparticles, and self-nanoemulsifying drug delivery systems showed reduce systemic side effects, improved therapeutic efficacy, and increased intestinal absorption. Besides LNDDSs were used to target-delivery of BTZ to cancer.
Conclusion:
Overall, LNDDSs can be considered as a novel delivery system for BTZ to resolve the treatment-associated restrictions.
Related Concept Videos
Bioavailability Enhancement: Drug Permeability Enhancement
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Biopharmaceutics and Pharmacokinetics: Overview
Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Factors Affecting Dissolution: Particle Size and Effective Surface Area

